Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Genmab A/S ADR (GMAB)

Genmab A/S ADR (GMAB)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
18.39 -0.85 (-4.42%) 04/04/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 18.39 unch (unch) 17:28 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
18.30
Day High
18.89
Open 18.80
Previous Close 19.24 19.24
Volume 2,472,500 2,472,500
Avg Vol 1,795,235 1,795,235
Stochastic %K 16.38% 16.38%
Weighted Alpha -40.50 -40.50
5-Day Change -1.51 (-7.59%) -1.51 (-7.59%)
52-Week Range 18.30 - 30.41 18.30 - 30.41
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,732,416
  • Shares Outstanding, K 661,768
  • Annual Sales, $ 3,121 M
  • Annual Income, $ 1,137 M
  • EBIT $ 972 M
  • EBITDA $ 1,032 M
  • 60-Month Beta 1.07
  • Price/Sales 3.99
  • Price/Cash Flow 12.41
  • Price/Book 2.34

Options Overview Details

View History
  • Implied Volatility 57.38% ( +8.02%)
  • Historical Volatility 47.47%
  • IV Percentile 59%
  • IV Rank 43.96%
  • IV High 112.31% on 06/26/24
  • IV Low 14.29% on 05/10/24
  • Put/Call Vol Ratio 10.82
  • Today's Volume 130
  • Volume Avg (30-Day) 188
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 16,891
  • Open Int (30-Day) 17,066

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.26
  • Number of Estimates 6
  • High Estimate 0.40
  • Low Estimate 0.18
  • Prior Year 0.16
  • Growth Rate Est. (year over year) +62.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.30 +0.49%
on 04/04/25
Period Open: 23.33
24.33 -24.40%
on 03/07/25
-4.94 (-21.17%)
since 03/04/25
3-Month
18.30 +0.49%
on 04/04/25
Period Open: 21.47
24.33 -24.40%
on 03/07/25
-3.08 (-14.35%)
since 01/03/25
52-Week
18.30 +0.49%
on 04/04/25
Period Open: 29.65
30.41 -39.53%
on 05/15/24
-11.26 (-37.98%)
since 04/04/24

Most Recent Stories

More News
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?

AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II studies on emraclidine, its once-daily...

NVO : 62.55 (-6.78%)
GMAB : 18.39 (-4.42%)
LLY : 738.21 (-6.45%)
ABBV : 186.96 (-7.28%)
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock?

Investors in Genmab A/S GMAB need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 15, 2024 $17.50 Call had some of the highest implied volatility...

GMAB : 18.39 (-4.42%)
Should You Buy AbbVie Stock After Recent Parkinson's Study Success?

Last week, AbbVie ABBV announced that a pivotal phase III study evaluating pipeline candidate tavapadon for treating early Parkinson's disease met the primary endpoint. The candidate was added to AbbVie’s...

NVO : 62.55 (-6.78%)
GMAB : 18.39 (-4.42%)
LLY : 738.21 (-6.45%)
ABBV : 186.96 (-7.28%)
AbbVie Stock Up Almost 20% in 3 Months: Buy, Sell or Hold?

AbbVie ABBV stock has gained 19.4% in the past three months compared with an increase of 8.1% for the industry. The stock has also outperformed the sector and S&P 500 index as seen in the chart below.ABBV...

NVO : 62.55 (-6.78%)
LLY : 738.21 (-6.45%)
ABBV : 186.96 (-7.28%)
GMAB : 18.39 (-4.42%)
Forget Weight-Loss Drugs, Here's the Next Breakthrough Pharma Stock

There is another segment of the pharma industry that is as hot as weight-loss drugs: antibody-drug conjugates, or ADCs. These treatments will, in the near future, replace conventional chemotherapy, thanks...

PFE : 22.97 (-5.43%)
ABBV : 186.96 (-7.28%)
JNJ : 153.24 (-4.12%)
RHHBY : 37.6500 (-5.92%)
GMAB : 18.39 (-4.42%)
AZN : 68.46 (-7.39%)
DSNKY : 24.0000 (-1.80%)
MRK : 81.47 (-5.70%)
LLY : 738.21 (-6.45%)
NVO : 62.55 (-6.78%)
Why Shares of Iovance Biotherapeutics Dropped Thursday

The biotech stock's lead therapy is looking at some competition.

SGEN : 228.74 (-0.07%)
GMAB : 18.39 (-4.42%)
IOVA : 3.00 (-7.69%)
Why Shares of Zai Lab Limited Were Jumping on Tuesday

Zai Lab's shares benefited from positive clinical trial news.

ZLAB : 31.77 (-13.41%)
SGEN : 228.74 (-0.07%)
GMAB : 18.39 (-4.42%)
Is AbbVie Still a Good Dividend Stock to Buy?

Find out if AbbVie can overcome sinking sales of its top-selling product.

ABT : 124.44 (-5.46%)
RHHBY : 37.6500 (-5.92%)
AMGN : 294.39 (-4.99%)
GMAB : 18.39 (-4.42%)
ABBV : 186.96 (-7.28%)
3 Things About Johnson & Johnson Every Smart Investor Knows

The company has been a strong value stock but faces big changes this year.

KVUE : 22.33 (-5.46%)
AMGN : 294.39 (-4.99%)
GMAB : 18.39 (-4.42%)
JNJ : 153.24 (-4.12%)
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?

In May, the FDA approved epcoritamab, developed by AbbVie and Genmab, as a treatment for a type of blood cancer.

ABBV : 186.96 (-7.28%)
GMAB : 18.39 (-4.42%)
AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

/PRNewswire/ -- AbbVie (NYSE: ABBV) and Genmab (Nasdaq: GMAB) today announced topline results from the follicular lymphoma (FL) cohort of the Phase 1/2 EPCORE™...

ABBV : 186.96 (-7.28%)
GMAB : 18.39 (-4.42%)
Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

Genmab A/S (Nasdaq: GMAB) and argenx (Euronext & Nasdaq: ARGX) announced today that Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel...

GMAB : 18.39 (-4.42%)
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Genmab A/S (Nasdaq: GMAB):

GMAB : 18.39 (-4.42%)
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S (Nasdaq: GMAB) today announced the results from multiple clinical trials evaluating epcoritamab (DuoBody ® -CD3xCD20), an investigational subcutaneous bispecific antibody, alone or in...

GMAB : 18.39 (-4.42%)
3 Hot Stocks That Could Live Up to Their Lofty Valuations

These companies have long runways of growth ahead

RHHBY : 37.6500 (-5.92%)
JNJ : 153.24 (-4.12%)
NVS : 105.85 (-5.71%)
ABBV : 186.96 (-7.28%)
GTBIF : 5.0200 (-5.82%)
SPWR : 0.1228 (-5.47%)
GMAB : 18.39 (-4.42%)
Is AbbVie Stock a Buy Now?

The pharmaceutical company prepared well as Humira approaches its patent cliff next year.

ABT : 124.44 (-5.46%)
AMGN : 294.39 (-4.99%)
GMAB : 18.39 (-4.42%)
ABBV : 186.96 (-7.28%)
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for subcutaneous epcoritamab (DuoBody®-CD3xCD20)...

GMAB : 18.39 (-4.42%)
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)

Genmab A/S (Nasdaq: GMAB) announced today that 19 abstracts evaluating various investigational medicines in its pipeline have been accepted for presentation at the 64 th Annual Meeting and Exposition...

GMAB : 18.39 (-4.42%)
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab A/S (Nasdaq: GMAB) today announced that the company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab (DuoBody®-CD3xCD20),...

GMAB : 18.39 (-4.42%)
ABBV : 186.96 (-7.28%)
3 Hail Mary Plays to Bring Your Stock Portfolio Back From the Brink

You may have to take a shot on some riskier plays if you want to make up your portfolio's significant loss of yardage.

ABBV : 186.96 (-7.28%)
RIVN : 11.21 (-2.78%)
S : 16.91 (-5.58%)
GMAB : 18.39 (-4.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 19.34
2nd Resistance Point 19.11
1st Resistance Point 18.75
Last Price 18.39
1st Support Level 18.16
2nd Support Level 17.94
3rd Support Level 17.58

See More

52-Week High 30.41
Fibonacci 61.8% 25.78
Fibonacci 50% 24.35
Fibonacci 38.2% 22.93
Last Price 18.39
52-Week Low 18.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades